General

Godavari Biorefineries reports sharp profit surge

For Q3 FY26, the company reported total income of Rs. 461.9 crore, up 2.5% year-on-year, with EBITDA rising 13.8% to Rs. 45.1 crore

Godavari Biorefineries, one of India’s leading ethanol producers and a pioneer in bio-based specialty chemicals, posted robust financial results for Q3 and nine months ended December 31, 2025, highlighting strong profitability and strategic growth in high-margin segments.

For Q3 FY26, the company reported total income of Rs. 461.9 crore, up 2.5% year-on-year, with EBITDA rising 13.8% to Rs. 45.1 crore and PBT before exceptional items surging 152% to Rs. 21.4 crore. EBITDA margins expanded to 9.8%, up 97 basis points, while PBT margins improved to 4.6%, marking a significant turnaround from the prior year.

Segment snapshots:

Bio-Based Chemicals: Rs. 10.9 crore, up 76.7% YoY

Sugar & Cogeneration: Rs. 32.1 crore, up 28.1% YoY

Ethanol: Rs. 4.2 crore, down 56.6% YoY

Commenting on the results, Samir Somaiya, CMD, said: "Q3 FY26 marked a quarter of significantly improved profitability, driven by operating leverage and disciplined execution. EBITDA grew approximately 14% year-on-year to Rs. 45.1 crore, while PBT before exceptional items surged 152% year-on-year to Rs. 21.4 crore. Our margins also expanded meaningfully as we focus more on high-margin segments, reinforcing the company’s strategic direction.

"inance costs for the quarter declined by 46% year-on-year, in line with our strategy to improve cash flows to fuel growth. The Bio-based Chemicals segment continued to support profitability, with specialty chemicals contributing 62% of the basket in 9M FY26, and we expect this share to rise further as we scale high-value offerings."

He added: "A key highlight during the period was the grant of a US patent for our novel anti-cancer molecule targeting triple-negative breast cancer, underscoring the strength of our R&D capabilities and commitment to innovation-led growth. In parallel, our DME-to-CO₂ technology initiative is progressing well, with pilot plant activities underway.

"We recently collaborated with Synthomer, to develop bio-based alternatives to fossil-based monomers. Through this collaboration, Synthomer is commercialising bio-based butyl acrylate using GBL’s bio-based butanol, accelerating the industry’s transition to sustainable raw materials and reflecting our continued focus on sustainability, green chemistry, and next-generation energy solutions."